GLPBio

Azithromycin

Catalog No.: GC14507Purity:>98.00%Synonyms: CP 62,993
アジスロマイシンは、多数の細菌感染症の治療に有用なマクロライド系抗生物質です。

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。


Azithromycin
Cas No.: 83905-01-5
10mM (in 1mL DMSO)In Stock
$62.00
1
50mgIn Stock
$56.00
1
100mgIn Stock
$88.00
1
200mgIn Stock
$140.00
1
500mgIn Stock
$266.00
1

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.

Azithromycin (2 μM) augments rhinovirus-induced IFNβ expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but not knockdown of RIG-I, diminishes azithromycin (2 μM)-enhanced viral-induced IFNβ expression in asthmatic primary bronchial epithelial cells[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF-κB in endotoxin-challenged monocytic THP-1 cells[2].

Azithromycin (50 mg/kg) has no effect on bronchoalveolar lavage inflammatory parameters and LDH levels in a mouse model of asthma exacerbation. Azithromycin induces neither general inflammatory parameters nor LDH release in a mouse model of asthma exacerbation, and augments expression of interferon-stimulated genes and the pattern recognition receptor MDA5 but not RIG-I in exacerbating mice[1].

References:
[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18.
[2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853.

実験プロトコル (Protocol)

Trypanocidal activity experiment [1]:

Trypanosomes

T. congolense, T. b. brucei and T. evansi

Preparation method

The solubility of this compound in DMSO is > 30.1 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0.32 ~ 25 μM; 72 hrs

Applications

The IC50 values of Azithromycin for T. congolense, T. b. brucei and T. evansi were 0.19 ± 0.17, 3.69 ± 2.26 and 1.81 ± 1.82 μM, respectively.

Animal experiment [1]:

Animal models

Mice infected with T. congolense

Dosage form

50, 100, 200, 300 and 400 mg/kg; p.o.

Applications

In mice infected with T. congolense, Azithromycin dose-dependently killed T. congolense, with the initial clearance of the parasites from the peripheral circulation in all treatment groups. However, this was followed by a relapse resulting in the rapid growth of the parasites. On the other hand, the survival rate was significantly prolonged in all treatment groups. A number of mice survived in the 200, 300 and 400 mg/kg Azithromycin groups, while all mice in the control and the 50 and 100 mg/kg Azithromycin groups died.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Molefe NI, Yamasaki S, Macalanda AMC, Suganuma K, Watanabe K, Xuan X, Inoue N. Oral administration of azithromycin ameliorates trypanosomosis in Trypanosoma congolense-infected mice. Parasitol Res. 2017 Jul 4.

製品資料 (Product Documents)

Purity:>98.00%Appearance:A solid

化学的性質 (Chemical Properties)

CAS番号
83905-01-5
同義語
CP 62,993
SMILES
CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
分子式
C38H72N2O12
分子量
748.98
溶解性
≥ 30.05mg/mL in DMSO
保存条件
Store at -20°C
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for Azithromycin

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%